Losartan Potassium
Product Images NDC 54868-6117

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 54868-6117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tablets Usp 50 mg Label (6104)

This is a label of Losartan Potassium 584g distributed by Physicians Total Care. It contains the NDC code 54868-6104-0, lot number q080, and an expiration date of 61460. The rest of the text is not legible or recognizable.*

FDA Label Image

Losartan Potassium Tablets Usp 100 mg Label (6107)

This is a medication distributed by Physicians Total Care with an NDC code of 54868-6107-0. The name of the medication is "LOSHRTAN POTASSIU 160G" and it appears to come in a quantity of 600. However, the remaining characters are not legible and do not provide any additional information.*

FDA Label Image

Losartan Potassium Tablets Usp 25 mg Label (6117)

FDA Label Image

Chem Structure For Losartan Potassium (B0445fa2 0e1a 4978 B49a B52fd494d568 01)

FDA Label Image

Figure 1 (B0445fa2 0e1a 4978 B49a B52fd494d568 02)

This appears to be a comparison of two drugs, Atenolol and Losartan potassium, in terms of their impact on a primary endpoint in a group of patients. The percentage of patients experiencing the endpoint is not provided, but a risk reduction of 13% was observed in the group receiving Losartan potassium, with a p-value of 0.021 indicating statistical significance. The data is presented over a 66-month study period.*

FDA Label Image

Figure 2 (B0445fa2 0e1a 4978 B49a B52fd494d568 03)

The text provided shows data related to a study comparing the effectiveness of two drugs, Atenolol and Losartan potassium, in reducing the risk of fatal or non-fatal stroke in patients. The study shows an adjusted risk reduction of 25% with a p-value of 0.001. There is a graph displaying the study month and the percentage of patients with stroke over time.*

FDA Label Image

Figure 3 (B0445fa2 0e1a 4978 B49a B52fd494d568 04)

FDA Label Image

Figure 4 (B0445fa2 0e1a 4978 B49a B52fd494d568 05)

The text provides information on a study or clinical trial that involved patients experiencing an event. The study compared the use of Losartan Potassium with the use of Placebo over a period of 24 months, with follow-up measurements taken at 36 and 48 months. The study found that the Risk Reduction with Losartan Potassium was 16.1% compared to Placebo, with a p-value of 0.022. This information could be useful for medical professionals and researchers interested in the efficacy of Losartan Potassium in managing events in patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.